Abstract:Head and neck squamous cell carcinomas (HNSCCs) are amongst the most aggressive, complex, and heterogeneous malignancies. The standard of care treatments for HNC patients include surgery, radiotherapy, chemotherapy, or their combination. However, around 50% do not benefit while suffering severe toxic side effects, costing the individuals and society. Decades have been spent to improve HNSCC treatment outcomes with only limited success. Much of the research in HNSCC treatment has focused on understanding the genetics of the HNSCC malignant cells, but it has become clear that tumour microenvironment (TME) plays an important role in the progression as well as treatment response in HNSCC. Understanding the crosstalk between cancer cells and TME is crucial for inhibiting progression and treatment resistance. Cancer-associated fibroblasts (CAFs), the predominant component of stroma in HNSCC, serve as the primary source of extra-cellular matrix (ECM) and various pro-tumoral composites in TME. The activation of CAFs in HNSCC is primarily driven by cancer cell-secreted molecules, which in turn induce phenotypic changes, elevated secretive status, and altered ECM production profile. Concurrently, CAFs play a pivotal role in modulating the cell cycle, stemness, epithelial-mesenchymal transition (EMT), and resistance to targeted and chemoradiotherapy in HNSCC cells. This modulation occurs through interactions with secreted molecules or direct contact with the ECM or CAF. Co-culture and 3D models of tumour cells and other TME cell types allows to mimic the HNSCC tumour milieu and enable modulating tumour hypoxia and reprograming cancer stem cells (CSC). This review aims to provide an update on the development of HNSCC tumour models comprising CAFs to obtain better understanding of the interaction between CAFs and tumour cells, and for providing preclinical testing platforms of current and combination with emerging therapeutics.

Crosstalk between cancer‐associated fibroblasts and immune cells in cancer

Interaction of Cancer-Associated Fibroblasts and Tumor Cells in Carcinogenesis

Cancer‐associated Fibroblasts in Breast Cancer: Challenges and Opportunities

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

[Progress on Cancer Associated Fibroblasts in Tumor Immunoregulation].

Cancer-Associated Fibroblasts Suppress Cancer Development: The Other Side of the Coin

Crosstalk and Plasticity Driving Between Cancer-Associated Fibroblasts and Tumor Microenvironment: Significance of Breast Cancer Metastasis

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Cancer-associated Fibroblasts: Just on the Opposite Side of Antitumour Immunity?

Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells

Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential

Cancer Associated Fibroblasts: an Essential Role in the Tumor Microenvironment

Crosstalk between cancer and immune cells: Role of tumor‐associated macrophages in the tumor microenvironment

CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?

CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion

Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: New frontiers and unveiled opportunities for cancer immunotherapy

Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment

Crosstalk between CAFs and tumour cells in head and neck cancer

Cancer-associated fibroblasts: heterogeneity and their role in the tumor immune response